Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo
Abstract We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-01602-w |